Abstract 215P
Background
Immunotherapy (IO) using programmed cell death protein 1 inhibitors is the standard of care in recurrent/metastatic head and neck cancer (R/M HNSCC). While response rate is almost 20% in the total population, a small percentage of patients shows exceptional response. Here, spatial whole transcriptome data were analysed to investigate potential compartment-specific associations of RNA expression with exceptional response to (IO).
Methods
Prospectively collected pre-treatment biopsies and clinicopathologic data of 50 IO-treated patients with R/M HNSCC were included in the study. Exceptional response (ER) was defined as complete or partial response (RECIST 1.1), lasting longer than 3 times the median response duration found in literature for the same treatment setting. Samples were evaluated using the GeoMx Human Whole Transcriptome Atlas (NanoString) assay for the in-situ quantification of 18,677 genes in the tumor (CK), leukocyte (CD45) and macrophage (CD68) tissue compartments. Differentially expressed genes (P<0.05, FDR 0.05) between ER and non-ER cases were identified in each compartment. Immune cell genes extracted from the “Single Cell RNA-Seq HNSCC” (CIBERSORTx) gene matrix and clinicopathologic characteristics; smoking, alcohol, sex, age, primary site and PD-L1 status, were investigated for correlations with ER.
Results
Seven exceptional responders were identified. Five immunoglobulin (Ig) genes (IGHG1, IGHG2, IGHG3, IGHG4, IGLL5) and one B-cell related gene (MZB1) showed the highest expression for exceptional responders both in the CD45 and CD68 compartments (stroma). Follicular dendritic cell secreted protein gene (FDCSP) was highly expressed in tumor. There was no association of ER with the immune-cell phenotypes derived from CIBERSORTx deconvolution. Alcohol consumption was the only clinicopathologic characteristic that showed association with ER (P=0.047).
Conclusions
ER to IO in R/M HNSCC is characterized by increased expression of Ig and B-cell related genes in tumor and stroma, indicating the importance of secreted immune factors for durable IO responses.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
D. Rimm: Financial Interests, Personal, Advisory Board: AstraZeneca, Agendia, Cell Signaling Technology, Amgen, BMS, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, Konica/Minolta, GSK, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi, Ventana; Financial Interests, Institutional, Funding: Amgen, Cepheid, NavigateBP, NextCure, Konica/Minolta. A. Psyrri: Financial Interests, Personal, Invited Speaker: MSD, Merck Serono, EPICS; Financial Interests, Personal, Advisory Board: Pfizer, Sanofi, MSD, AstraZeneca, BMS, Leo, Rakuten, eTheRNA immunotherapies, Merck Serono, Seagen, Merus, Merus Pharmaceuticals, GSK; Financial Interests, Personal and Institutional, Local PI: AstraZeneca, Pfizer, GSK, Genesis, Incyte, Amgen, Debiopharm, MSD, Janssen, Lilly, Regeneron, Sanofi, BI, Roche, Peregrine, Oncolytics Biotech; Financial Interests, Personal, Coordinating PI: AstraZeneca; Financial Interests, Personal and Institutional, Steering Committee Member: Iovance, Pfizer, Roche; Financial Interests, Institutional, Steering Committee Member: Kura Oncology; Financial Interests, Personal, Steering Committee Member: Kura Oncology, GSK, Merus Pharmaceuticals; Financial Interests, Personal and Institutional, Funding: Kura Oncology, BMS, Roche, DEMO, Amgen, BI, Genesis, BMS, Pfizer, Oncolytics Biotech; Financial Interests, Institutional, Funding: Merck Serono, Pfizer, GSK; Financial Interests, Personal, Other, Educational activity: Medscape, Prime Oncology; Financial Interests, Institutional, Local PI: Novartis, Replimune. All other authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
Resources:
Abstract
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
Resources:
Abstract
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
Resources:
Abstract
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
Resources:
Abstract
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
Resources:
Abstract
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
Resources:
Abstract
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
Resources:
Abstract
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
Resources:
Abstract
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session
Resources:
Abstract
133P - The efficacy and safety of KN046 combined with axitinib for previously untreated and checkpoint inhibitor treated advanced non-small cell lung cancer: A single-arm, open-label, multicenter phase II clinical trial
Presenter: Li Zhang
Session: Poster Display session
Resources:
Abstract